ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-VEGF Antibody-drug Conjugate YL242

Also written as “YL242”, “YL242; Pembrolizumab” and “YL242; 5-FU; LV”.

Its studies are mostly in Neoplasms, led by MediLink Therapeutics (Suzhou).

Furthest: phase 2, since Sep 26, 20251 company-led study, 1 open or runningNext primary completion: Sep 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediLink Therapeutics (Suzhou)11 open or runningphase 2since Sep 26, 2025Sep 26, 2025Sep 2028phase 2 · NCT07197827

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2025First study: phase 2 study in NeoplasmsFirst studyNCT07197827 · 424 planned · United States, Australia, China

Ahead

  1. Sep 2028Primary completion: phase 2 study in NeoplasmsNCT07197827

TargetBeta

VEGFA →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the human vascular endothelial growth factor (VEGF) ”NCIt, by rule

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
BevacizumabruleHoffmann-La Rochephase 4250
RanibizumabruleNovartisphase 4108
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
suvemcitugruleSimcere Pharmaceutical Groupphase 36
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
surabgene lomparvovecAbbViephase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07197827Neoplasms · United States, Australia, China2RecruitingSep 2028424

How it is read

Names in the registry

  • “YL242”, 1 entry
  • “YL242; Pembrolizumab”, 1 entry
  • “YL242; 5-FU; LV”, 1 entry
  • “YL242; Pembrolizumab; 5-FU”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.